MilliporeSigma CEO Eyes New Technologies, Simpler Process for CAR-T Manufacturing

Vector supply isn’t the only challenge to the development and manufacturing of chimeric antigen receptor T-cell (CAR-T) therapies. The process of producing and delivering the therapies to patients can take 30 to 40 days, relying on cumbersome methods based on older cell expansion technologies repurposed for CAR-T.In addition to expanding vector supply to meet growing demand, MilliporeSigma CEO Udit Batra, Ph.D., told GEN , his company is working to unclog two other bottlenecks to CAR-T dev